INHALANT GLUCOCORTICOID APPLICATION EXPERIENCE AMONG INFANTS WITH BRONCHOPULMONARY DYSPLASIA IN THE FIRST HALF YEAR OF LIFE

The article describes the modern views on the application of the inhalant glucocorticoids (budesonide suspension) among infants, who underwent artificial pulmonary ventilation at the neonatal stage and who had bronchopulmonary dysplasia formed. The authors performed the clinical and functional evaluation of their state owing to the bronchophonography along with the follow up observation until 6 month of life.Key words: artificial pulmonary ventilation, bronchopulmonary dysplasia, extremely low body weight, bronchophonography, acoustic work of breathing

INHALANT GLUCOCORTICOID APPLICATION EXPERIENCE AMONG INFANTS WITH BRONCHOPULMONARY DYSPLASIA IN THE FIRST HALF YEAR OF LIFE

The article describes the modern views on the application of the inhalant glucocorticoids (budesonide suspension) among infants, who underwent artificial pulmonary ventilation at the neonatal stage and who had bronchopulmonary dysplasia formed. The authors performed the clinical and functional evaluation of their state owing to the bronchophonography along with the follow up observation until 6 month of life.Key words: artificial pulmonary ventilation, bronchopulmonary dysplasia, extremely low body weight, bronchophonography, acoustic work of breathing

ALLERGIC RHINITIS AS A RISK FACTOR OF THE DEVELOPMENT OF BRONCHIAL ASTHMA IN CHILDREN

In the article the problems of classification, diagnostics and treatment of allergic rhinitis in children are viewed, the therapy with local antihistamines is detailed. The state of bronchial reactivity in children with allergic rhinitis has been studied, the methods of the prophylaxis of bronchial asthma progress are discussed.Key words: allergic rhinitis, bronchial asthma, azelastine, children, treatment.</p

ALLERGIC RHINITIS AS A RISK FACTOR OF THE DEVELOPMENT OF BRONCHIAL ASTHMA IN CHILDREN

In the article the problems of classification, diagnostics and treatment of allergic rhinitis in children are viewed, the therapy with local antihistamines is detailed. The state of bronchial reactivity in children with allergic rhinitis has been studied, the methods of the prophylaxis of bronchial asthma progress are discussed.Key words: allergic rhinitis, bronchial asthma, azelastine, children, treatment

ANTI-IGE THERAPY FOR SEVERE ASTHMA IN CHILDREN: TWO-YEAR TRIAL

The article summarizes a two-year experience of treating children and adolescents with severe uncontrolled atopic asthma using Omalizumab. This treatment facilitated to achieve full asthma control in 70% of patients and partial control in 30% of patients. Anti-Ig Etherapy contributes to reduce the frequency of asthma relapses 77%, and the number of those seeking emergency medical treatment, particularly no need for in-patient asthma care. Thanks to treatment, lung function parameters improve, particularly in children with low bronchial patency parameters even after administration of broncholytics. Thanks to treatment with omalizumab, the dosage of inhalant glucocorticosteroids is reduced 1.5 to 2.5 times in 75% patients. Treatment tolerance in all children is satisfactory, no serious adverse events associated with the medication or any system side effects are registered in patients. Anti-IgE therapy is a good alternative to use of high and ultra-high doses of inhalant glucocorticosteroids in children with severe atopic asthma. Key words: omalizumab, anti-IgE-antibodies, treatment-resistant asthma, atopic asthma, treatment, children, adolescents, asthma control. (Pediatric Pharmacology. – 2010; 7(3):57-65

ANTI-IGE THERAPY FOR SEVERE ASTHMA IN CHILDREN: TWO-YEAR TRIAL

The article summarizes a two-year experience of treating children and adolescents with severe uncontrolled atopic asthma using Omalizumab. This treatment facilitated to achieve full asthma control in 70% of patients and partial control in 30% of patients. Anti-Ig Etherapy contributes to reduce the frequency of asthma relapses 77%, and the number of those seeking emergency medical treatment, particularly no need for in-patient asthma care. Thanks to treatment, lung function parameters improve, particularly in children with low bronchial patency parameters even after administration of broncholytics. Thanks to treatment with omalizumab, the dosage of inhalant glucocorticosteroids is reduced 1.5 to 2.5 times in 75% patients. Treatment tolerance in all children is satisfactory, no serious adverse events associated with the medication or any system side effects are registered in patients. Anti-IgE therapy is a good alternative to use of high and ultra-high doses of inhalant glucocorticosteroids in children with severe atopic asthma. Key words: omalizumab, anti-IgE-antibodies, treatment-resistant asthma, atopic asthma, treatment, children, adolescents, asthma control. (Pediatric Pharmacology. – 2010; 7(3):57-65

MODERN TRENDS IN THE PHARMACOTHERAPY FOR ALLERGIC RHINITIS AMONG CHILDREN

The article analyzes own and literature based data on the effeciency of treatment for allergic rhinitis among children assisted by the blocker of H1-histamine dezloratadine (Aerius) and topical corticosteroid mometazone (Nazonex) receptor.Key words: children, allergic rhinitis, treatment, antihistamines, topical glucocorticosteroids

EFFICIENCY OF MONTELUKAST TREATMENT OF THE CHILDREN, SUFFERING FROM BRONCHIAL ASTHMA

The aim of the present open research was to assess the montelukast efficiency among 41 children, suffering from bronchial asthma. the age of patients was between 6 and 15 years old. Clinical and functional efficiency of montelukast was noted among 85,4% of the patients. montelukast treatment contributed to the decrease of the bronchial asthma recrudescence frequency, reduction of the number of the used betab2bprotoganists, inhaled glucocorticosteroids and increase of tolerance towards the physical load.Key words: bronchial asthma, montelukast, children, treatment

ОПЫТ ПРИМЕНЕНИЯ ИНГАЛЯЦИОННЫХ СТЕРОИДОВ У ДЕТЕЙ С БРОНХОЛЕГОЧНОЙ ДИСПЛАЗИЕЙ В ПЕРВОМ ПОЛУГОДИИ ЖИЗНИ

The article describes the modern views on the application of the inhalant glucocorticoids (budesonide suspension) among infants, who underwent artificial pulmonary ventilation at the neonatal stage and who had bronchopulmonary dysplasia formed. The authors performed the clinical and functional evaluation of their state owing to the bronchophonography along with the follow up observation until 6 month of life.Key words: artificial pulmonary ventilation, bronchopulmonary dysplasia, extremely low body weight, bronchophonography, acoustic work of breathing.В статье отражены современные взгляды на применение ингаляционных стероидов (суспензии будесонида) у детей, перенесших искусственную вентиляцию легких в неонатальном периоде и сформировавших бронхолегочную дисплазию. Авторы изучили эффективность препарата, выполнили клинико-функциональную оценку состояния пациентов с помощью бронхофонографии при катамнестическом наблюдении до 6 месяцев жизни.Ключевые слова: искусственная вентиляция легких, бронхолегочная дисплазия, экстремально низкая масса тела, бронхофонография, акустическая работа дыхания. (Педиатрическая фармакология. – 2008;5(6):42-44

АНТИ-IGE-ТЕРАПИЯ ТЯЖЕЛОЙ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ: ДВУХЛЕТНИЙ ОПЫТ

The article summarizes a two-year experience of treating children and adolescents with severe uncontrolled atopic asthma using Omalizumab. This treatment facilitated to achieve full asthma control in 70% of patients and partial control in 30% of patients. Anti-Ig Etherapy contributes to reduce the frequency of asthma relapses 77%, and the number of those seeking emergency medical treatment, particularly no need for in-patient asthma care. Thanks to treatment, lung function parameters improve, particularly in children with low bronchial patency parameters even after administration of broncholytics. Thanks to treatment with omalizumab, the dosage of inhalant glucocorticosteroids is reduced 1.5 to 2.5 times in 75% patients. Treatment tolerance in all children is satisfactory, no serious adverse events associated with the medication or any system side effects are registered in patients. Anti-IgE therapy is a good alternative to use of high and ultra-high doses of inhalant glucocorticosteroids in children with severe atopic asthma. Key words: omalizumab, anti-IgE-antibodies, treatment-resistant asthma, atopic asthma, treatment, children, adolescents, asthma control. (Pediatric Pharmacology. – 2010; 7(3):57-65)В статье обобщается двухлетний опыт лечения омализумабом детей и подростков с тяжелой неконтролируемой атопической бронхиальной астмой. Данное лечение позволило добиться полного контроля болезни у 70% больных и частичного контроля бронхиальной астмы у 30% больных. Анти-IgE-терапия способствует снижению частоты обострений бронхиальной астмы на 77%, а также обращений за экстренной медицинской помощью, в том числе отсутствию потребности в стационарном лечении по поводу астмы. На фоне лечения улучшаются показатели функции легких, в том числе у детей с низкими показателями бронхиальной проходимости даже после приема бронхолитиков. Доза ингаляционных глюкокортикостероидов на фоне лечения омализумабом снижена у 75% больных в 1,5-2,5 раза. Переносимость лечения у всех детей удовлетворительная, ни у кого из больных не отмечено серьезных нежелательных явлений, связанных с препаратом, а также каких-либо системных побочных эффектов. Анти-IgE-терапия является хорошей альтернативой применению у детей с тяжелой атопической бронхиальной астмой высоких и сверхвысоких доз ингаляционных глюкокорткостероидов. Ключевые слова: омализумаб, анти-IgE-антитела, резистентная к терапии бронхиальная астма, атопическая бронхиальная астма, лечение, дети, подростки, контроль бронхиальной астмы. (Педиатрическая фармакология. – 2010; 7(3):57-65